12-month real-world achievements for Diabeloop's AID PARIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- EASD 2022 - Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports today on 12 months of use of its hybrid closed-loop DBLG1 System on a...

Diabeloop - Key Player in Therapeutic AI Applied to Insulin Delivery - Announces 70 Million Euros New Financing Round to Accelerate Its International Expansion PARIS, June 02, 2022 (GLOBE NEWSWIRE) -- Diabeloop secures 70 million euros to pursue its solid and sustained growth strategy. The automated insulin delivery pioneer, develops machine-learning...

Diabeloop Presents New Real-Life Results of DBLG1® System PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- At ATTD 2022 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in...

Diabeloop Adapts Its Self-Learning, Personalized Insulin Automatization Software to Be Used With Insulin Pens PARIS, April 12, 2022 (GLOBE NEWSWIRE) -- Diabeloop, a pioneer in the field of therapeutic artificial intelligence, leverages the potential of its diabetes technology to enable the integration of...

Terumo Corporation and Diabeloop SA Enter Into Comprehensive Strategic Partnership Agreement to Expand Their Diabetes Care Offerings TOKYO & PARIS, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Terumo Corporation, a global leader in medical technology, and the French company Diabeloop, a pioneer in therapeutic AI, announced today that...